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In  this  article,  we  elaborate  on  grey-area  concepts  in  elite  cycling.  First,  we  show  how  grey  areas  take
place  in  a certain  lack of  conceptual  clarity  in  anti-doping  regulations.  Then,  we analyse  the  changing
attitudes  of elite  cycling  stakeholders  towards  grey  zones.  Finally,  we  discuss  our  results  by  articulating





culture,  including  elite cycling.
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. Introduction
Anti-doping policies aim to preserve health and fairness, that
s what is deemed intrinsically valuable about sport. As a result,
arious lists of prohibited performance enhancing substances and
ethods (hereinafter referred to as performance enhancing drugs
r PEDs) have been developed since the 1960s. However, there was
onsiderable variation between sports disciplines and/or national
olicies regarding what was banned and what was not (Houlihan,
002). The World Anti-Doping Agency (WADA) was established in
999 to harmonise anti-doping regulations worldwide. Since its
ore document, the World Anti-Doping Code (WADC), was  adopted
n its first version in 2004, any use of a substance or method that
s not explicitly banned can be considered allowed. In fact, through
ts Prohibited List, which addresses numerous classes of substances
e.g., anabolic steroids, stimulants, diuretics) and methods (e.g.,
lood transfusions), WADA simply relies on the ‘principle of legal-
ty’, the legal ideal that requires all law to be clear, ascertainable,
nd non-retrospective, since it would be unfair to impose sanctions
or acts that were not illegal at the time of their commission (nullumPlease cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
Enhancement & Health,  https://doi.org/10.1016/j.peh.2020.100179
rimen sine lege: no crime without law) (Meron, 2011). However,
lthough WADA rules aim to establish clear distinctions between
anned and allowed activities, concepts such as enhancement or
 This manuscript has not been published and is not under consideration for pub-
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.0/).health cannot always be reduced to black and white categories.
Several enhancers are allowed or prohibited only under certain con-
ditions (e.g., in- or out-of-competition, or depending on whether
their use may  be justified by a therapeutic use exemption). Other
enhancers, such as several research chemicals, are simply not cov-
ered by anti-doping regulations. PEDs in the so-called ‘grey zone’
– i.e. products that are neither explicitly banned nor explicitly
allowed under WADA regulations (Van Thuyne, 2006) – are thus
increasingly considered a controversial issue within anti-doping
policies, and they can leave room for juridical insecurity.
Our theoretical framework primarily relies on Howard Becker’s
seminal theory of deviance (Becker, 1963). Becker argues that
deviance is not a quality of the act the person commits, but rather a
consequence of the application by others of rules and sanctions to
an offender. Performance enhancement covers a large array of prac-
tices but not all of them are labelled illicit by anti-doping authorities.
In fact, several effective enhancing substances and methods are
allowed, while others are not, and these labels may  change over
time: something that was authorized may  become prohibited,
and vice versa. For example, there are on-going debates about
substances such as glucocorticoids (Orchard, 2008) and cannabis
(Bergamaschi & Crippa, 2013). No substance or method is banned
for the sole reason that it is performance enhancing. Instead, a
PED is banned because it has been labelled banned by those who
are empowered to do so. Yet, the norms and values of the domi-
nant culture (i.e., those promoted today by WADA) may differ from of grey? On the concept of grey zones in elite cycling, Performance
other subcultural sets that then develop their own socializing pat-
terns (Berger & Luckmann, 1966; Ohl, Fincoeur, Lentillon-Kaestner,
Defrance, & Brissonneau, 2015; Pappa & Kennedy, 2013). In par-
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icular, Coakley (2015) demonstrated how doping practices could
e seen as ‘deviant overconformity’ by the sports subculture. That
s, PED-using athletes are actually complying with the expecta-
ions and standards of elite sport. The quest for performance drives
lite athletes and sports organisations, but debates exist about
he acceptable limits of performance enhancement (Loland, 2015).
arginal gains and the grey zone issue then raise important ques-
ions in this respect. As part of sporting culture, marginal gains
re often perceived positively by athletes and staff. They partici-
ate to the win-at-all-costs culture (Hughes & Coakley, 1991) in
hich athletes are socialised. However, this culture is challenged
y a culture of anti-doping. The WADA Code in each iteration has
haped a different approach to performance, defining more strictly
hat is allowed and not. Consequently, for some athletes and staff,
he sporting habitus for which marginal gains is part of the per-
ormance, contradicts the strict respect of the anti-doping rules
nd principles. Cycling is a sport in which grey areas have recently
eceived significant attention, and this article addresses how the
rey zone issue is perceived by elite cycling stakeholders. Further,
t explores how grey areas challenge the anti-doping debate more
roadly.
. Literature review: the growing debate about grey areas
nd its application to elite cycling
The doping grey zone may  be understood as the space where
EDs of unclear acceptability or legality in sport sit (Van Thuyne,
006). Unclear acceptability refers to how legitimately athletes per-
eive the use of certain PEDs, regardless of their legality. Unclear
egality, rather, derives from changing regulations and/or semi-
llegal status of PEDs in different contexts (e.g., allowed in country
, prohibited in country B). In addition, debates about grey zones
ften rest on the sometimes-unclear distinctions made between
oncepts such as therapy and enhancement, or enhancement and
oping. Owing partly to the lines and policies that determine these
istinctions being far from black and white, athletes who are actu-
lly in compliance with anti-doping rules may  find themselves
ccused of operating in the grey zone for various reasons. The grey
one consists of various shades of grey, each of which has its own
eculiarities and challenging issues for anti-doping.
One key grey zone is the use of prohibited substances for medical
easons. Understanding that athletes may  require the use of pro-
ibited substances for legitimate medical reasons, WADA sought to
raw a line between therapy and enhancement through Therapeu-
ic Use Exemptions (TUE). TUEs are exemptions for which athletes
ust apply and demonstrate that use of a prohibited substance is
equired. There are strict criteria for one to be granted: the ath-
ete would suffer significant health problems without taking the
ubstance, use under the TUE is highly unlikely to produce any
dditional significant enhancement of the performance, there is
o reasonable therapeutic alternative to the prohibited substance,
nd such need is not due to prior use without a TUE (WADC, 2018).
hile this looks like a reasonable accommodation to address the
ine between therapy and enhancement, in practice it has led to
uspicions around who gets TUEs and why (Bloodworth, Cox, &
cNamee, 2019). Two surveys of French-speaking and Danish ath-
etes found that many athletes thought TUEs were unnecessarily
ranted, and these feelings of mistrust were more likely if the sur-
eyed athlete had themselves received a TUE (Bourdon, Schoch,
roers, & Kayser, 2014; Overbye & Wagner, 2013).
Several athletes seemingly understand TUEs as a vehicle forPlease cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
Enhancement & Health,  https://doi.org/10.1016/j.peh.2020.100179
uthorized doping. This issue took on greater prominence in 2016
ollowing the release of athlete anti-doping records after a database
as hacked by the Fancy Bears group. Several high-profile athletes
ere found to have received previously undisclosed TUEs (Ingle, PRESS
e Enhancement & Health xxx (xxxx) xxx
2016a). Despite these athletes being transparent with anti-doping
officials about their use of prohibited substances and that use being
approved as necessary, questions swirled about potential misuse
of TUEs to gain an edge in competition (Ingle, 2016b). The hack-
ers are not the only ones who raised concerns about the misuse of
TUEs. According to Richard McLaren, the author of the report into
Russian doping, the TUE system is open to abuse (McLaren, 2016).
The Cycling Independent Reform Commission (CIRC) also found evi-
dence that the TUE programme was  being systematically abused to
enhance performance (Marty, Nicholson, & Haas, 2015). This raises
further questions about the integrity of the TUE process, as well
as the ease with which elite athletes are granted TUEs (Dasgupta,
2019; Gleaves et al., 2019). However, published evidence of TUE
abuse is scant, and anti-doping officials basically maintain that it is
hard to get a TUE and that there are very few that are applied for
and approved. The percentage of athletes competing with a valid
TUE at the Olympic Games is less than 1%, and there is “no meaning-
ful association between being granted a TUE and the likelihood of
winning a medal” (Vernec & Healy, 2020). A WADA official we inter-
viewed noted, ‘(when athletes) claim that the TUE system is one of
the principle areas of abuse, (. . .)  repetition of unsubstantiated claims
(. . .)  lend them an element of truth even if they are false statements.’
Another category of grey zone identified by researchers and
athletes is legal enhancers. These include substances, such as
painkillers and nutritional supplements, or methods, such as
hypoxic chambers. For example, athletes may  use supplements
for a variety of reasons, one of which is performance enhance-
ment. This is where the distinction between enhancement and
doping becomes blurred: something that enhances is not necessar-
ily doping, and vice versa. In the former case, many substances or
methods known to enhance are allowed in sport. Researchers have
debated the allowance of such substances as caffeine (Henne, Koh, &
McDermott, 2013; Marcora, 2016) and methods such as simulated
altitude (Levine, 2006; Malloy, Kell, & Kelln, 2007). While widely
accepted that both can enhance performance, they are nonetheless
allowed and therefore not considered doping. Conversely, use of
non-enhancing drugs may  be, or may  have been, considered dop-
ing. Several recreational drugs are or were prohibited by WADA at
various times in and out of competition. One drug currently prohib-
ited under certain circumstances is cannabis, despite its growing
acceptance as a therapeutic drug and new legislation allowing
recreational use. Debates over the inclusion of cannabis on the Pro-
hibited List continue (Henne et al., 2013; Kayser & O’Hare, 2013;
Waddington, Christiansen, Gleaves, Hoberman, & Møller, 2013).
Supplement use—including inadvertent or accidental ingestion
of prohibited substances through supplements—also form a major
grey zone issue (Henning & Dimeo, 2018; Martínez-Sanz et al.,
2017). This is of high importance due to the widespread use of sup-
plements among athletes (Knapik et al., 2016; Outram & Stewart,
2015), and the poor regulations around the manufacture of such
products. This then leaves athletes at risk of inadvertently testing
positive through supplement use (Denham, 2017; Mathews, 2018).
A study of WADA’s results management database found that up
to 40 % of all athletes sanctioned for a positive test were likely to
have unintentionally used a prohibited substance (de Hon & van
Bottenburg, 2017). When athletes use a product for enhancement
but do not intend to take a prohibited substance, the line between
enhancement and doping, and between doping and cheating, is
unclear at best (Pluim, 2008). WADA has clarified their position
through the application of strict liability, but concerns about ath-
letes being caught up in accidental use are not unwarranted (Cox,
2014; Moston & Engelberg, 2019). of grey? On the concept of grey zones in elite cycling, Performance
Finally, the grey zone also consists of unapproved or unreg-
istered PEDs. The Prohibited List contains section S0, according
to which ‘any pharmacological substance which is not addressed
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ent approval by any governmental regulatory health authority
or human therapeutic use (e.g. drugs under pre-clinical or clinical
evelopment or discontinued, designer drugs, substances approved
nly for veterinary use) is prohibited at all times.’ However, sec-
ion S0 acts as a kind of residual category to cover situations not
ncluded in the other sections of the WADC. This black box gener-
tes grey areas for potential PEDs users. It is unclear, for example,
hether a substance that is not listed and approved by several
ealth authorities is allowed or, in particular, if it has been approved
y several health authorities from countries with laxer regulations
han others. Such use could be seen as violating the ‘spirit of sport’
s described in the introduction of the WADC, because it concerns
nhancement that not all athletes would have access to, leading to
nfair competition. As such, there is room for discretionary power
ausing uncertainty for athletes (McNamee, 2015).
.1. Grey areas in elite cycling
There have been major changes with regard to riders’ atti-
udes and patterns of use towards PEDs over the last few years
Waddington, 2019). It is worth recalling that during the 1998
our de France, an investigation revealed systematic doping among
eams after a large haul of doping products was  found in a car
elonging to the Festina team a few days before the start of the
ace (Christiansen, 2005; Waddington & Smith, 2009). The peloton
hen staged a solidarity sit-down protest against doping allegations
rom the media and the fact that hotels were searched by police
Mignon, 2003). In the months following the scandal, the few riders
ho broke down the walls of silence and acknowledged that doping
as endemic to elite cycling were promptly fired from the peloton
Bassons, 2014). Like any other sport, elite cycling had to face the
xpansion and intensification of anti-doping policy from 1999. At
his point doping was described in language highlighting the harms
f doping to sport, health, and ethics, and the need to promote and
reserve ‘clean’ sports (Sandvik, 2019). As a result, the perceived
egitimacy of undisputable doping practices has decreased consid-
rably among riders (Ohl et al., 2015). This is due in part to the need
o restore riders’ and teams’ spoiled identities (Sefiha, 2017), and
lite cycling’s image in order to keep sponsorships (Dimeo, 2014).
Scandals pertaining to elite cycling over the last few years have
hown how blurred lines might in fact characterise the approach
owards performance enhancement, as well as part of the anti-
oping regime. In particular, several medical practices from Team
ky, one of the most successful elite cycling team of the last decade,
ere highlighted because they would have transgressed ethical
oundaries by misusing TUEs—a key grey zone we  identified. The
eport from the select committee that investigated Team Sky’s
ractices indicated that several riders were treated with drugs to
nhance the performance of riders and not just to treat medical
eed, although without violating WADA rules (House of Commons,
018). As we will show in the results section, the use of certain PEDs
as seen as a form of cheating not because they were on the banned
ist, but because they allegedly went against what was  deemed
orally acceptable, that is the ‘spirit of sport’ for which there is no
egal or uncontested basis (Kornbeck & Kayser, 2018; McNamee,
015). “Is it doping or is it just using the rules?” asked Interna-
ional Cycling Union (UCI) President David Lappartient according
o whom grey areas should be eradicated because they are likely
o damage cycling’s credibility (Cycling News, 2018). Similarly, as
arly as in July 2010, John Fahey, the former President of WADA,
laimed that taking caffeine pills was against the spirit of sport
Cooper, 2012a: 176). However, ‘one is left with the impressionPlease cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
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hat it is the implication that something is a medicine that is the
roblem, not the chemistry itself’ (Cooper, 2012b). (Elite) sport
s full of chemistry, such as the widespread use of supplements
mong athletes (Knapik et al., 2016), but the use of medication by PRESS
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athletes seems increasingly controversial. Research investigating
public opinion and attitudes towards doping has found no accep-
tance of ‘pure’ doping products, such as EPO, anabolic steroids,
and amphetamines (Engelberg, Moston, & Skinner, 2012; Stamm,
Lamprecht, Kamber, Marti, & Mahler, 2008). It is much less clear
with regard to PEDs that could be categorized as belonging to grey
zones, such as hypoxic chambers (Solberg, Hanstad, & Thøring,
2010). Although other sports have been affected by scandals related
to grey areas (Gordon, 2017; Walker, 2014), research pertaining to
attitudes on grey areas is scant. As such, we are focusing on this
issue with respect to elite cycling.
3. Methods
This article relies on aggregated results from two  main research
projects. First, we used the results from a doctoral dissertation
on doping in Belgian and French male elite cycling (2012–2016).
Second, this article is based on results from a three-year research
project funded by the Swiss National Science Foundation (SNF)
on performance enhancement in men’s elite cycling (2016–2019).
Seventy-seven and sixty-nine semi-structured interviews, respec-
tively, were conducted with elite riders, staff members (team
managers, sports directors, team physicians), and other stakehold-
ers (anti-doping policy-makers at WADA and UCI, sports agents,
journalists). Interviewees within elite cycling teams belong(ed)
to either WorldTour or ProContinental teams, the two top-tier
divisions in elite cycling. The teams represent a diverse range of
demographics, originating from countries that have a strong tradi-
tion in cycling (e.g., Belgium, France, Italy) and those that do not
(e.g., Anglo-saxon countries). Interviewees came from a large array
of countries: Austria, Belgium, Canada, Estonia, France, Germany,
Italy, Kazakhstan, the Netherlands, Spain, South Africa, Switzerland,
and UK. Riders included those who  were present in the ‘old gener-
ation’ of cycling who were active from the early 1990s on, and up
to the new generation of riders who  were only at the beginning of
their careers.
Interviewees were selected by convenience and/or snowball
sampling (Emerson, 2015). There was no requirement for riders
or staff to participate and all interviews were given on a volun-
tary basis. Each interviewee was informed of the purpose of the
project, and that the study was independently funded and not
attached to any cycling or anti-doping governing bodies. Interviews
were conducted in English, French, Dutch, Italian, or Spanish, either
at the home of interviewees or in hotels during races or training
camps. Several participants were interviewed up to four times in
order to better understand the longitudinal evolution in the atti-
tudes towards doping – i.e., do interviewees stick to their initial
views or can we observe some shift in their attitudes depending
on environmental factors such as the changing economic context
of cycling and advances in anti-doping? Multiple interviews also
allowed us to deal with some provisional results in depth. Field
notes and observations were also recorded in order to engage in a
self-reflexive analysis of the data. The data collection period was
spread out over several years (2012–2019). As a result, we ben-
efit from a longitudinal perspective that enabled us to track the
evolution in the doping-related attitudes within elite cycling.
Each interview was  transcribed verbatim. Open coding of the
transcripts was utilized in order to establish a broader sense
of understanding of pertinent themes for further investigation.
Data were processed using Nvivo. The analysis was  cross checked
for inter-observer reliability. A basic content analysis was  imple- of grey? On the concept of grey zones in elite cycling, Performance
mented and involved treating each interview as one unit of analysis.
The Nvivo software facilitated the coding process and the organisa-
tion of the interview data into nodes, which allows researchers to
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006). Although grey areas were not a research question from
he very beginning of the research project, the topic progressively
merged from the data analysis as a key issue for anti-doping and
 primary concern for cycling stakeholders.
. The increasingly negative attitudes towards grey areas
mong cycling stakeholders
Important changes in the line-up of the medical staff of elite
eams have taken place over the last decade. Undoubtedly, the
istory of sports doping is intertwined with that of sports physi-
ians, who played a prominent role in prescribing, monitoring,
nd/or providing athletes with prohibited PEDs (Brissonneau &
ontez de Oca, 2018; Paoli, 2019; Waddington, 1996). Elite cycling
s no exception. For instance, EPO turned out to be endemic in the
id-1990s after a biomedical research team from the Italian Uni-
ersity of Ferrara ensured its appropriate use among elite riders
Donati, 2012). There is strong evidence of the embeddedness of
eam physicians within the doping supply chains, at least until the
arly 2000s. Team-unrelated doctors began to play an increased
ole from the mid-2000s as a result of changes in elite cycling
nd in anti-doping policies (Fincoeur et al., 2019). Since then,
lite teams have been increasingly committed to a new approach
o anti-doping (Ohl et al., 2019). As a result, many ‘old’ doctors
ave modified their practices and are now expected to supervise
heir riders rather than aid them in outperforming their competi-
ion.
‘Due to the new team policy and the various scandals elite
cycling has faced these past few years, I am now expected to
behave like a policeman who is supposed to verify that his riders
are compliant with anti-doping rules. I understand this because
I don’t want to be responsible for making sixty people unem-
ployed but, basically, my  motivation to do this job got lost”
(Team doctor).
In addition, a new generation of team doctors, with little to
o background in the ‘dark period of cycling’ (i.e., the period of
idespread doping between the early 1990s and the end of the
rmstrong years), is replacing the older generation that worked
hrough the team-sponsored doping era. This new generation cur-
ently in the field has established a new doxa or “an agreement to
omply with an order which, as a compulsory element for under-
tanding the world, is accepted without asking” (Bourdieu, 1996:
71). This generation does not hold the same attitudes towards
EDs as their predecessors, and no longer considers them as a legit-
mate mean to obtain cycling results.
“I think I would be really uncomfortable using a product (in the
grey zone) purely because it boils down to the spirit of sport and
you know, if we knew about something that directly enhances
performance and no other teams knew about it, that’s really
defined the whole spirit of sport because then you are on a dif-
ferent level to everyone else. (. . .)  I still think it crosses that
ethical line and my  job is not to be getting someone a medication
purely to increase their performance” (Team doctor).
Doctors’, sports directors’ and riders’ views on enhancement
ave seemingly turned into a clear-cut division between accept-
ble and unacceptable PEDs. While this shift may  be understood
egarding banned PEDs, there is a trend towards defining PEDs in
eneral as unacceptable (‘deviant’ in Becker’s words). Hence, wePlease cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
Enhancement & Health,  https://doi.org/10.1016/j.peh.2020.100179
laborate and focus on elite cycling stakeholders’ attitudes towards
rey zones. In particular, we emphasise that TUEs, hypoxic cham-
ers, painkillers, and supplements, are increasingly labelled deviant
hough they are not prohibited. PRESS
e Enhancement & Health xxx (xxxx) xxx
4.1. Complaints about the (mis)use of therapeutic use exemptions
Our results show that false TUEs—TUEs without any medical
reason—fall under the new moral condemnation of doping. Top
riders recently complained about the alleged TUE-related mis-
conduct and criticised the UCI for its weakness in managing the
crisis (Cycling Weekly, 2017). The controversy around Team Sky
(Bloodworth et al., 2019) illustrates these complaints and suspi-
cions over how TUEs are delivered, regardless of whether riders’
perceptions are well-founded or not. Cycling actors today are
calling for a tougher stance on practices that come to be seen
as ‘artificially performance enhancing.’ Top French rider Romain
Bardet demanded a stricter approach on the use of corticoids (Le
Monde, 2016), which are authorised out of competition and by
request via TUE in competition, depending on the administration
mode:
“The real problem is that corticoids are permitted. One prohibits
lots of products but not corticoids, although they have anti-
inflammatory properties and enhance the performance. There
are far too many riders in the peloton – and we riders all know
them – who  allegedly have knee problems before their ath-
letic objectives and use unnatural products for that purpose.
Then, the day of the competition, you see chubby guys with
very skinny legs, no one is credulous”.
In the same vein, Belgian Tim Wellens preferred to abandon the
2018 Tour de France rather than accept a TUE, seemingly for fear of
reputational damage (L’Equipe, 2018). Similarly, most of our inter-
viewees, especially riders in the first half of their career and “new”
team doctors, reported very uncomfortable feelings with TUE.
“I understand that a rider can be sick and require some med-
ication. But one should not exaggerate. Otherwise, everybody
can tell he’s asthmatic. I’m aware several riders have borderline
practices but my  generation we really try to do the job clean. If
you need medication, you stay at home. Modern doping, it’s not
testing positive but playing with the limits and unfortunately
I’m aware that several riders behave in that way” (Rider).
“A big concern is grey areas where it’s not necessarily illegal but
it’s certainly unethical and cortisone is a big one. (. . .)  I’ve never
once written a TUE for cortisone in my  career. It’s very perfor-
mance enhancing and we know that, and yes just disappointing
that it’s not on the banned list” (Team doctor).
Surprisingly, it is not only the misuse of TUEs that has become
controversial. Since the TUE regime is viewed as open to abuse,
even legitimate TUEs have begun to raise questions among riders
and staff. Other enhancement techniques provide further evidence
of the retreat from both authorized and banned PEDs. Similar resis-
tance to allowed enhancers is observed with regard to hypoxic
chambers, painkillers, and supplements.
4.2. When authorized enhancers turn undesirable
Since EPO is prohibited by anti-doping regulations, one could
argue that the legality of simulated altitude, either with hypobaric
or with normobaric hypoxic chambers, is purely an application of
Becker’s labelling theory, as explained above (Becker, 1963). Both
EPO and hypoxic chambers can increase the quantity of red blood
cells to improve aerobic performance. But while EPO users need
syringes as a means of improving their athletic performance, ath- of grey? On the concept of grey zones in elite cycling, Performance
letes using hypoxic chambers only need to sleep in them as part
of their training regimen. In the end, both techniques have similar
purposes to training at high altitude, but only EPO is deemed to
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Given both means could be said to meet two  of the three cri-
eria for including substances and methods on the Prohibited List
i.e. potential to enhance sport performance and violation of the
pirit of sport), several authors suggest that there is no moral
ifference between using EPO and a hypoxic chamber (Levine,
006; Malloy et al., 2007). Although results are not uncontrover-
ial (Millet, Chapman, Girard, & Brocherie, 2019), other research
as shown that the “live high, train low” (LHTL) approach, which is
he idea behind hypoxic chambers, has no greater effect on perfor-
ance output measured in watts or on any relevant physiological
arameters than does “live low, train low” (LLTL) (Bejder et al.,
017; Siebenmann et al., 2012). However, WADA regulations do
istinguish between the two techniques, as EPO use is banned while
ypoxic chambers are not. Nevertheless, the latter are prohibited in
taly and there have been debates over their inclusion on the WADA
rohibited List (Lippi, Franchini, & Guidi, 2007). This values-driven
nconsistency in how EPO and hypoxic chambers are treated by
nti-doping policy-makers contributes further to the grey zone.
“As an Italian citizen, I may  not use a tent when I’m at home.
But several of my  teammates, who live abroad, have the right
to do so. And if I’m out of Italy? What am I supposed to do?
This situation is beyond understanding! What is the rule? We
all do the same job but we do not have the same opportunities.
I don’t know if tents should be allowed or not, but please apply
the same regulations everywhere” (Rider).
Yet, no matter the potential similarity of effects of these two
erformance-enhancing techniques, most elite cycling stakehold-
rs make a clear distinction between them. Although EPO was
idespread at least until the late 1990s (Gleaves et al., 2019), its
se is now condemned by an overwhelming majority of riders
nd there is evidence that most elite teams, if not all, no longer
upply their riders with EPO (Fincoeur, van de Ven, & Mulrooney,
014). The changing attitudes towards EPO use could also be influ-
nced by the ‘no needle policy’ that was adopted by the UCI in
011 (Cycling News, 2013). The UCI Regulations prohibit injec-
ions with the aim of artificially improving performance or helping
ecovery. This means riders can no longer inject vitamins, sugars,
nzymes, amino acids, or antioxidants to aid recovery. The UCI Reg-
lations only allow injections when they are medically justified and
hen there is no alternative treatment available (Lopez, 2017). In
 context where elite cycling needs to provide evidence of its com-
itment to clean sport, our interviewees increasingly considered
ypoxic chambers to be part of the grey zone. They tended to label
heir use as undesirable because it could harm the efforts of elite
ycling to convince stakeholders that cycling is now committed to
clean sport’.
“Well, our team leader does use a hypoxic chamber. . . I don’t
know if there is academic research on the acceptance of alti-
tude chambers by the public and cycling fans, and I know the
technique is not illegal according to anti-doping rules but, due
to its past, elite cycling today needs to be totally clean” (Team
manager).
“I have heard that L. has equipped his whole flat in hypoxia. I
don’t know how much it has costed but that is very borderline,
I think. That is a bit unfair. He plays with the rules” (Rider).
The reluctant attitudes towards hypoxic chambers echo similar
hanging attitudes towards the use of supplements and painkillers.
arthe and Maughan (2018) have shown that between 40 % and 100
 of athletes typically use supplements, depending on the type of
port and the level of competition. Since small factors can com-Please cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
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ound to impact the outcome of sporting contests, supplements
ay  actually be seen as part of a ‘marginal gains’ approach. The
otion of marginal gains was popularised by Dave Brailsford, team PRESS
e Enhancement & Health xxx (xxxx) xxx 5
manager of Team Sky, who applied this approach to cycling (Harrell,
2015) and made it an important communication strategy for his
team. Marginal gains consist of the 1 % margin for improvement
in everything riders and teams do. The main idea is that if one
improves every area related to cycling by just 1 %, then those
small gains are expected to add up to remarkable improvement.
Marginal gains include optimisation of: nutrition, training pro-
grammes, ergonomics of the bike seat, weight of wheels, etc. It also
covers improvement in tiny areas that are usually overlooked, such
as using the most effective type of massage gel or the pillow that
offers the best sleep. To be clear, in our research we did not find any-
one who  disagreed with the objective of improving a training plan
or body posture on the bike. However, we did find various stake-
holders who  perceive supplements as enhancers that they ideally
would do without. Young riders in particular seem to be increas-
ingly educated to consider supplements as something unnecessary
and alien to the needs of an elite athlete.
“Especially when I discuss with some of our old sports direc-
tors, I sometimes struggle to change mentalities within the team
about the use of supplements but I try to convince them that it
is not a good signal for our young riders. It suggests that an elite
rider needs something artificial to do the job” (Team manager).
There is some evidence that supplement use is a step towards
further medication, including prohibited PEDs (Hurst, Kavussanu,
Boardley, & Ring, 2019). This view understands the use of supple-
ments in ways similar to the ‘gateway hypothesis,’ a theory that
suggests early experimentation with legal or social drugs escalates
to addictive illicit drugs later in adulthood (Kandel, 2002; Lynskey,
Heath, & Bucholz, 2003).
Similar conclusions can be drawn regarding painkillers. In a con-
text where athletes are looking for the outer edge of their potential
in order to win, painkillers may  also simply be overused to cope
with pressure to perform through pain at high levels (Selanne et al.,
2014; Tscholl, Feddermann, Junge, & Dvorak, 2009). Although using
painkillers is authorized, the deputy director of the World Anti-
Doping Laboratory in Cologne explained that analgesic use ‘is a grey
zone. (. . .)  Painkillers fulfill all requirements of a doping substance
because normally pain is a protection mechanism of the body and
with painkillers you switch off this protection system’ (McNamee,
2014: 191). Just like supplements, and despite some doubts about
effectiveness (Da Silva, Pinto, Cadore, & Kruel, 2015), the use of
painkillers and sleeping tablets in the peloton has long been con-
sidered part of the life of an elite rider. Here again, voices are now
being raised against the use of anything that is related to pharmaco-
logical assistance, even when authorized. The British elite rider Alex
Dowsett spoke out against this pill culture: ‘There is still reliance on
things that come in a tablet form. In every team that I’ve been in, the
doctor does the rounds at night and it’s not a case of if they want
the sleeping tablet, it’s how many, or which ones’ (Smith, 2014).
From our interviewees, we  collected numerous similar accounts.
“What I don’t think is normal is when I see, during the races,
numerous riders taking a Tramadol (= a painkiller) for the last
100 km.  It is very common, even among my teammates, but
that’s not my  conception of cycling” (Rider).
Importantly, UCI decided to start tramadol testing in January
2019. Tramadol is an opiate that is not on the WADA Prohibited List,
but the UCI President announced several painkillers to be banned:
‘Tramadol is a problem in cycling, we  needed to do something about
it’ (Velonews, 2018). It is worthwhile to note that the painkillers
described here are widely used outside of sport for treating minor of grey? On the concept of grey zones in elite cycling, Performance
ailments. In fact, this is no more than an additional illustration of the
changing culture towards PEDs in elite cycling. Any enhancers are
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ithin a sports community whose new doxa is articulated around
laims of purity in order to restore a tarnished image and attract
ponsorships.
.3. The grey zone pushes back its frontiers
Our results highlight a major evolution in the perception of what
alls under grey areas, and about how these grey areas are being
onsidered among insiders. This evolution is summarized in our
ig. 1 below. In fact, elite cycling stakeholders increasingly tend
o label PEDs, including authorized ones, as deviant, and therefore
lien to cycling culture. While grey areas, just like marginal gains,
id not raise a major issue a decade ago (bottom-right in Fig. 1), they
re now undesirable for an increasing number of cycling actors,
ven though their use is not problematic from a legal perspective
top right-hand corner in our figure). Of course, this is not a minor
volution if looking back at the recent history of doping in elite
ycling. This is where Becker’s theoretical framework comes into
lay.
The scholarly community has documented that although EPO
se was prohibited, a widespread culture of tolerance towards PEDs
as entrenched in elite cycling, and many doping products were
ot considered deviant within elite cycling until the late 1990s
r early 2000s (bottom-left of Fig. 1) (Brissonneau & Montez de
ca, 2018; Christiansen, 2005). Yet, there is evidence that elite
ycling has faced several major changes regarding patterns of dop-
ng use over the last two decades (Waddington, 2019). In particular,
ncreased anti-doping efforts and the incremental confessions of
ifferent riders helped break down cycling’s secret doping culture
Dimeo, 2014). As a result, while the (il)licit status of PEDs may  have
emained unchanged, their perceived legitimacy (i.e. deviant char-
cter) within cycling may  switch from acceptable to unacceptable.
 distinction therefore needs to be made between deviance and
elinquency. Although a delinquent necessarily breaches regula-
ions, the deviant is one to whom a negative label has successfully
een applied (Becker, 1963). Following a secondary socialisation
rocess through which the athlete learns standards, values, and
now-how, and the language of the environment step by step
Berger & Luckmann, 1966), what falls under a deviant label may
nclude or exclude new practices.
Various grey zone enhancers are increasingly considered con-
roversial, and their use is consequently perceived deviant among
he cycling community. In this regard, the grey zone is extending its
rontiers. Yet, it is worth emphasizing a paradox around grey areas:
thletes or riders using grey areas still keep up with all means to
mprove their performance, and outperforming is the spirit of (elite)
port. Labelling grey areas as deviant seems contradictory given
he widely accepted performance-driven culture endorsed in elite
port. Most interviewees acknowledged, for example, that Team
ky’s marginal gains approach gave a real boost to the entire elite
ycling community.
“Team Sky’s approach brought a lot to cycling. They really
wanted to reach the top in each aspect. They were very
methodic. But in fact, this has helped all teams to be more pro-
fessional, to question themselves, to be innovative. According
to me,  cycling should be just grateful to them” (Rider).
Any quest for performance enhancement was praised. In fact,
arginal gains are commonplace and desirable except when theyPlease cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
Enhancement & Health,  https://doi.org/10.1016/j.peh.2020.100179
ome out of pharmacological assistance, even when compliant with
he WADC. How can we understand the recent questions raised by
he ketone regime allegedly used by several elite teams otherwise
Cary, 2018; Cycling Weekly, 2019)? PRESS
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5. Discussion and conclusion: quest for performance
enhancement vs grey areas
Given the amount of money from sponsors required to keep elite
cycling alive, it is not unreasonable that cycling stakeholders would
take a hard line on the types of doping that have plagued the sport
in recent decades (Dimeo, 2014). Regaining credibility for the sport
in order to keep and attract new investments was  crucial in the
wake of high-profile scandals (Waddington & Smith, 2009). How-
ever, this drive for ‘clean’ sport has led to a new brand of cycling
puritanism as well as a new brand of deviance. The need to maintain
an image of drug-free sport has made athletes and support per-
sonnel fearful of appearing unethical for seeking even completely
legal enhancements. Where cyclists had previously been happy to
use grey zone products and seek out innovative, boundary pushing
technologies (Ohl et al., 2015; Waddington, 2019), cyclists now fear
the backlash of potential criticism of any perceived deviance. This
transformed culture seems to have bred a new conservatism, taking
much of the excitement and innovation out of many aspects of the
sport. In the push to avoid becoming delinquent under WADA rules,
many are now doing all they can to avoid being labeled deviant
(Ohl et al., 2019). Several claims in the media, such as those from
the Movement for Credible Cycling (MPCC) (Fincoeur, 2016), and
new UCI policies may  suggest that cycling culture has turned very
orthodox. This new orthodoxy is illustrated by the imposition of
stricter rules than even those required by WADA (e.g., controversy
about the use of tramadol in Baltazar-Martins et al., 2020). As a
result, elite riders must navigate an expanding grey zone in addi-
tion to anti-doping regulations, which further adds uncertainty
in yet precarious work conditions (Fincoeur, Cunningham, & Ohl,
2018).
The dynamic and growing Prohibited List compounds this chal-
lenge. The IOC Medical Commission, as well as the scientific
community and the sporting world, did not know what to make
of blood transfusions in the mid-1970s. As reported by Llewellyn,
Gleaves, and Wilson (2015: 95), some academic researchers sug-
gested reclassifying blood transfusions as a ‘grey zone of legality’
alongside selected vitamins and minerals, food supplements, or
other drugs consumed for therapeutic or gastronomical reasons.
This temptation to lump ever more substances and methods into
the grey zone under the guise of ‘clean sport’ is strong for ath-
letes and policymakers, as it serves as a shield against impropriety.
Many grey zone PEDs actually fall into clearer categories of allowed
or not allowed (Solberg et al., 2010). Depending on their specific
contents, painkillers, supplements, and hypoxic chambers can be
put into these categories. But lingering perceptions lead to uncer-
tainty, which leads to more additions to the grey zone, a cycle that
continuously repeats.
Expanding grey zones also calls into question the contempo-
rary emphasis on continuing improvements in sport performance
in areas such as race times, records, and margins of victory. Athletes
are encouraged to exceed previous performances through team
and sponsorship contracts, media and fan expectations, and high-
performance culture. Such advances would likely require athletes
to undertake some behaviours currently understood as deviant,
such as using of grey zone PEDs. However, these same forces simul-
taneously demand adherence to a partly unclear set of expectations
around enhancement and deviance. These contradictory expec-
tations pose a conundrum to cyclists: continue to use whatever of grey? On the concept of grey zones in elite cycling, Performance
authorized means necessary to continue to improve, but avoid any-
thing that might be called into question despite its compliance
with WADC. Rather than clarifying, this aversion to being viewed
as deviant adds further shades to the grey zones.
ARTICLE IN PRESSG ModelPEH-100179; No. of Pages 9


















































Fig. 1. Perceived Legitimacy vs. Legal S
As the boundaries of acceptability shrink, the grey zone seems
o expand to engulf ever more legal, or at least not prohibited,
ubstances and methods. As Brands (2016) noted about military
onflicts, grey is becoming the new black and deviance inching
loser to delinquency. Grey zones are becoming so large and sweep-
ng that any explanatory power drawn from the concept is lost and
he category becomes meaningless. The price, then, is increased
mbiguity. Not only ambiguity for athletes who must constantly
emain on the ‘right’ side of the shifting ethical line, but also for
olicy-makers who have to determine how to respond to grey zones
n ways that are consistent, logical, and fair.
The WADA Code is already a very complex policy that was not
ell understood by many of the riders we interviewed. Confu-
ion about anti-doping rules can create uncertainty for cyclists.
o address these issues, there have been calls for reforming
nti-doping that may  help clarify policies for athletes. One such
uggestion is to shorten the Prohibited Substances List (e.g. Kayser,
019; Overbye, 2018; Pielke & Boye, 2019). A shortened List could
ocus on substances and methods that have either a scientifically
upported enhancing effect (Pielke & Boye, 2019) or that pose an
ctual (rather than potential) threat to athlete health (Kayser, 2019;
verbye, 2018). By limiting the List to these categories may  also
ore clearly delineate what is allowed in sport and reduce negative
erceptions of current grey zone substances and reduce anxieties
round their use. Outside of sport, individuals are rarely reluctant
o use products such as painkillers or supplements. Moreover, in a
ports context, little is known of the ergogenic effects and poten-
ial side effects of products such as tramadol in cycling (Holgado
t al., 2018). This approach could further help minimise the risks of
he professional and social stigmatisation athletes face when they
istakenly appear in the headlines for alleged doping practices.
he case of the salbutamol use by British multiple Tour de France
inner Christopher Froome is illustrative of reputation damage
esulting from an unclear policy towards grey areas (Heuberger,
an Dijkman, & Cohen, 2018).
For these reasons, academic work on grey zones across sport
s warranted to understand if these patterns hold in different con-
exts. We  see two main avenues of future research. First, prevalence
ork that includes grey zones in addition to clearly prohibited PEDs
s necessary. Current prevalence studies tend to exclude grey zones,
ikely for a variety of definitional and clarity reasons. However,
mproving our understanding of how widely used these are could
nform both how we understand doping behaviours and how policy
s understood practically. Second, there is need for more quali-
ative work focused on athletes’ perceptions of grey zones. This
s particularly important on the question of TUE misuse (Gleaves
t al., 2019), including if this process occurs, in what ways it isPlease cite this article as: B. Fincoeur, A. Henning and F. Ohl, Fifty shades
Enhancement & Health,  https://doi.org/10.1016/j.peh.2020.100179
ble to happen, and how athletes view themselves and others who
se the system this way. Researchers have suggested ending the
UE program (Dimeo & Møller, 2018) but the extent of this issue
emains unclear. In-depth research would provide an evidence baseof Performance-Enhancement Modes.
for doping policy-makers seeking to prevent TUE abuse. It would
also provide better insight into how anti-doping may be structured
for athletes’ benefit.
Declaration of Competing Interest
None.
Acknowledgments
This study was  funded by the research grant “Cycling Culture,
Organisations and Doping” from the Swiss National Science Foun-
dation.
References
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